Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7.
about
Shiga toxin interaction with human intestinal epitheliumAdvances in pathogenesis and therapy of hemolytic uremic syndrome caused by Shiga toxin-2The bacterial chemical repertoire mediates metabolic exchange within gut microbiomesMicrobiota and pathogen 'pas de deux': setting up and breaking down barriers to intestinal infection.Probiotics, enteric and diarrheal diseases, and global health.Prophage induction is enhanced and required for renal disease and lethality in an EHEC mouse model.Shiga toxin production and translocation during microaerobic human colonic infection with Shiga toxin-producing E. coli O157:H7 and O104:H4Chemical sensing in mammalian host-bacterial commensal associations.Initial adherence of EPEC, EHEC and VTEC to host cells.The highly virulent 2006 Norwegian EHEC O103:H25 outbreak strain is related to the 2011 German O104:H4 outbreak strain.A comparison of Shiga-toxin 2 bacteriophage from classical enterohemorrhagic Escherichia coli serotypes and the German E. coli O104:H4 outbreak strain.Microbiota-mediated colonization resistance against intestinal pathogens.Milk sialyllactose influences colitis in mice through selective intestinal bacterial colonization.The gut bacterium Bacteroides thetaiotaomicron influences the virulence potential of the enterohemorrhagic Escherichia coli O103:H25Enterohemorrhagic Escherichia coli infection has donor-dependent effect on human gut microbiota and may be antagonized by probiotic yeast during interaction with Peyer's patches.Vitamin B12 Uptake by the Gut Commensal Bacteria Bacteroides thetaiotaomicron Limits the Production of Shiga Toxin by Enterohemorrhagic Escherichia coliPresence of pathogenic Escherichia coli is correlated with bacterial community diversity and composition on pre-harvest cattle hidesThe struggle within: microbial influences on colorectal cancer.Coculture of Escherichia coli O157:H7 with a Nonpathogenic E. coli Strain Increases Toxin Production and Virulence in a Germfree Mouse ModelBacterial symbioses of the medicinal leech Hirudo verbana.Role of host xanthine oxidase in infection due to enteropathogenic and Shiga-toxigenic Escherichia coli.Modulation of the enterohemorrhagic E. coli virulence program through the human gastrointestinal tract.Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.Enteric pathogen exploitation of the microbiota-generated nutrient environment of the gut.Probiotic and enterohemorrhagic Escherichia coli: An effective strategy against a deadly enemy?Predominance of Lactobacillus spp. Among Patients Who Do Not Acquire Multidrug-Resistant OrganismsPutative adhesins of enteropathogenic and enterohemorrhagic Escherichia coli of serogroup O26 isolated from humans and cattle.Enterohemorrhagic Escherichia coli O157:H7 survival in an in vitro model of the human large intestine and interactions with probiotic yeasts and resident microbiota.Comparing the microbiota of the cystic fibrosis lung and human gut.Chemical signaling in the gastrointestinal tract.Mariner-based transposon mutagenesis for Bacteroides species.Protective Microbiota: From Localized to Long-Reaching Co-Immunity.Iron supplementation promotes gut microbiota metabolic activity but not colitis markers in human gut microbiota-associated rats.Differential expression of virulence and stress fitness genes during interaction between Listeria monocytogenes and Bifidobacterium longum.A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile.Non-pathogenic Escherichia coli Enhance Stx2a Production of E. coli O157:H7 Through Both bamA-Dependent and Independent Mechanisms.
P2860
Q26850758-CC53B51E-FA70-4A7B-91A3-830D20619FBAQ26863602-FD5053DB-9BF5-4EA1-A559-0EAAA0F0BE89Q27000963-D99F07F3-64D7-4AA6-9687-E50647ED0844Q30276689-4DA06CB2-335D-4B4A-9BFE-4876A7D7D707Q30425561-0769D149-C383-402C-8683-C70976D10421Q33406825-965EE20B-0F33-4EEA-9B29-7A72A937DC4AQ33413792-A9F709EF-9CCA-44A4-80EB-214705F286A5Q34006799-0B1DA50F-8810-4F59-AA00-94A6185F0236Q34112426-2698C634-5DE1-4D68-90EF-1CEC725BAEEFQ34189292-06343A10-2700-4192-927A-94C00033BE9BQ34287467-7F73CB5C-A4DD-4B09-B77C-7FA2CA9B51EFQ34324937-47360ECB-6561-4929-8C89-016C300E95BAQ34420808-CF7D367A-3977-4C03-8856-DE0E43A978FFQ35568020-A2845813-12F0-4152-9B3D-D50BCE76BEB6Q35666705-161C7F75-3FD8-4C8A-A909-417BA7D2CDC4Q35888177-DEF4BA56-0987-4E97-A121-D1C208744541Q35965328-C5969046-F850-480C-9973-5E4D6689BD0DQ36036277-594B6D4C-802E-471A-9A14-1C53ECD1DE89Q36137954-C1B06C06-A913-46D9-B5A5-CBFA519EA4CAQ36295238-5393F580-80E7-4050-A8EC-2C9A1355FC57Q36804725-FB2F85C0-E392-4970-96A7-E54BF5200995Q37009028-42B74CDF-6A89-43E9-BE3B-1D4B1FC431CBQ37218835-3670B7B2-B9FA-48BB-A278-E9334490F336Q37826861-676828A4-7B5F-4763-8B12-B06EB610496AQ38995452-49B1CAAE-B62B-40A0-91DC-A8E35092F1D9Q40631019-DEEEC67E-73E7-4B9D-976E-D0831011BB1FQ41883310-B0873F41-BFA1-4586-9885-99D834AB3212Q42119561-E22ACFAC-7AB7-4528-A04F-31283C7A7E7EQ42575595-05CFDA5E-D73C-4623-8DE7-3AEF871CB239Q42618951-98194DE5-A918-47E2-BC89-E228FF148BC5Q43168130-D1058A21-DD70-4065-A307-0FDB02D06335Q47152495-B01E4CCB-99F1-4D66-90CA-E8D4CEAD4A37Q51752289-0BCC87E5-D8FC-4893-A919-5DA0A7C92E87Q54315762-88C2E176-706C-427E-96F2-93C653F1C084Q55333418-FE431921-6EDE-4F54-8774-BB0A5B01916BQ55416818-8B0BB5B7-01EB-4927-ACB5-E9B9817AE975
P2860
Human microbiota-secreted factors inhibit shiga toxin synthesis by enterohemorrhagic Escherichia coli O157:H7.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@en
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@nl
type
label
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@en
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@nl
prefLabel
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@en
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@nl
P2093
P2860
P356
P1476
Human microbiota-secreted fact ...... agic Escherichia coli O157:H7.
@en
P2093
Alain P Gobert
Annick Bernalier-Donadille
Christine Martin
Christophe Chassard
Marjolaine Vareille
Thibaut de Sablet
P2860
P304
P356
10.1128/IAI.01048-08
P407
P577
2008-12-08T00:00:00Z